Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(25%)

Phase Distribution

Ph not_applicable

75%

Ph phase_3

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 3Large-scale testing

1(25.0%)

N/ANon-phased studies

3(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(1)

Other(2)

Detailed Status

unknown2

Terminated1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 3

Trials by Phase

Phase 31 (25.0%)

N/A3 (75.0%)

Trials by Status

terminated125%

completed125%

unknown250%

Recent Activity

0 active trials

Showing 4 of 4

completednot_applicable

Efficacy of Corneal Cross-Linking (CXL) in the Treatment of Pediatric Keratoconus

NCT07080983

unknownnot_applicable

Transepithelial Customized Cross-linking

NCT04820608

terminatednot_applicable

Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study. (CXL)

NCT02088970

unknownphase_3

Refractive Treatment of Early Keratoconus

NCT02613780

Clinical Trials (4)

Showing 4 of 4 trials

NCT07080983Not Applicable

Efficacy of Corneal Cross-Linking (CXL) in the Treatment of Pediatric Keratoconus

Completed

NCT04820608Not Applicable

Transepithelial Customized Cross-linking

Unknown

NCT02088970Not Applicable

Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study. (CXL)

Terminated

NCT02613780Phase 3

Refractive Treatment of Early Keratoconus

Unknown

All 4 trials loaded

Drug Details

Intervention Type: DEVICE
Total Trials: 4